

Zen Technologies

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	ZEN IN
Equity Shares (m)	90
M.Cap.(INRb)/(USDb)	152.4 / 1.6
52-Week Range (INR)	2024 / 1223
1, 6, 12 Rel. Per (%)	-4/37/-2
12M Avg Val (INR M)	1022

Financials Snapshot (INR b)

Y/E MARCH	FY27E	FY28E	FY29E
Sales	9.9	13.7	17.5
EBITDA	3.6	5.0	6.4
EBITDA Margin (%)	35.9	36.4	36.4
PAT	3.0	4.2	5.3
EPS (INR)	33.6	47.0	58.8
EPS Growth (%)	107.8	40.0	25.1
BV/Share (INR)	235.4	282.4	341.2

Ratios

Net D/E	-0.6	-0.6	-0.6
RoE (%)	15.4	18.2	18.9
RoCE (%)	15.5	18.3	19.0

Valuations

P/E (x)	50.3	35.9	28.7
P/BV (x)	7.2	6.0	5.0
EV/EBITDA (x)	39.9	28.1	21.7

Shareholding pattern (%)

As Of	Jun-26	Mar-26	Jun-25
Promoter	48.5	48.5	49.1
DII	10.4	10.1	8.8
FII	6.9	6.4	6.5
Others	34.2	35.0	35.7

FII includes depository receipts

CMP: INR1,690 **TP: INR1,600 (-5%)** **Neutral**

Execution to improve from 2HFY27

Zen Technologies (ZEN)'s 1QFY27 result was weaker than our estimates due to lower-than-expected execution and higher other expenses, which affected its EBITDA margin. Orders started flowing in from Jul'26, and we expect further inflows from simulator orders worth ~INR7-8b, followed by anti-drone orders. We also expect the execution ramp-up to be largely visible from 2HFY27 owing to the inflows of FY26. The company is continuously adding new capabilities to widen its portfolio of offerings, and going forward, we also expect subsidiaries to witness an improvement in inflows. We largely maintain our estimates and reiterate our Neutral rating on the stock with a TP of INR1,600 based on 30x Sep'28E earnings. Order inflows and improvement in execution will be the key re-rating drivers for the stock going forward.

A weak set of results

ZEN reported a weak set of results with a miss across revenue, EBITDA, and PAT. Revenue declined 7% YoY to INR1b, missing our estimate by 6%. Gross margins surged to 65.7% (55.1% last year) during the quarter vs. our estimate of 55.0%. However, due to a spike in other expenses, EBITDA margin contracted 690bp YoY to 27.4% vs. our estimate of 28.5%. The absolute EBITDA declined 26% YoY to INR282m (9% below our estimates). Lower execution and margin contraction led to a 21% YoY dip in PAT to INR292m vs. our estimate of INR333m. The standalone order book as of the end of 1QFY27 grew 88% YoY to ~INR11.4b, whereas the consolidated order book stood at INR12.4b, indicating subsidiaries' OB of ~INR1b.

Inflow and execution to pick up in 2HFY27

ZEN's consolidated order book stood at INR12.4b as of Jun'26, comprising INR9.2b of equipment orders and INR3.2b of AMC orders. At the standalone level, the order book stood at INR11.4b, with equipment orders of ~INR8.4b (55% anti-drone, 34% simulator), and AMC of ~INR3b. Post quarter-end, the company secured an additional INR1.8b order from the Ministry of Defence for the upgradation and integration of tank and crew gunnery simulators, taking the executable consolidated order book to ~INR14.2b. The company expects to end FY27 with an order book of around INR25b, after factoring in order execution during the year, supported by a healthy pipeline across simulators and anti-drone systems. Simulator orders worth INR7-8b remain in the pipeline, with additional orders expected over the next few months as government procurement gains momentum. The company also reiterated that the current order book has a typical execution cycle of around 12 months, with execution weighted towards 2HFY27. We expect standalone inflows/revenue to clock a CAGR of 32%/60% over FY26-29.

Gradual expansion in export markets

Management expects exports to become a more meaningful growth driver, supported by rising global defense spending and increasing demand for training simulators and anti-drone solutions. The company is expanding beyond its traditional export markets in the Middle East, Africa, Southeast Asia and CIS

countries into North America and Europe, initially through partnerships with established defence contractors before pursuing direct opportunities. The addressable market for the simulator portfolio in the US alone stands at ~USD10b over the next three years, with the company targeting ~USD100m of revenue from the US market by the third year.

Expanding defense capabilities through subsidiaries

Vector Technics, the company's drone propulsion subsidiary, has expanded its manufacturing capacity to approximately 300,000 propulsion units and supplies products to domestic drone manufacturers as well as export customers. Nearly 50% of recent inquiries have originated from overseas markets, including Europe and the US, although industry-wide delays in drone procurement have slowed near-term order inflows. Depending on order conversion, Vector Technics has the potential to generate INR1-3b of annual revenues at current capacity utilization. Separately, ZEN continues to evaluate acquisitions to strengthen its technology portfolio, supported by its debt-free balance sheet, cash balance of around ~INR12.2b, and balance proceeds from the earlier QIP.

Margins affected by cost absorption

The company attributed the lower EBITDA margin during the quarter primarily to negative operating leverage arising from lower revenue absorption of fixed costs, with revenue expected to improve as execution accelerates through the year. Margins were also impacted by the absence of INR77m of provision reversals recorded in 1QFY26, along with higher warranty provisions of INR29m and incremental R&D expenditure of ~INR43m during the quarter. The company reiterated its expectation of achieving a mid-30% EBITDA margin for FY27 as execution scales up over 2QFY27 and 3QFY27.

Broadening solutions across the core and emerging segments

ZEN expects simulators to contribute ~INR20b (50%) of its targeted cumulative revenue of INR40b during FY27-FY28, supported by opportunities across the Army, Navy, and Air Force, including the C-295 flight simulator. Management expects anti-drone procurement to accelerate with fast-track government tenders, while the man-portable anti-drone system remains under armed forces evaluation. Beyond its core businesses, it is also developing an Integrated Smart Border Management System, Hyper-Strike interceptor drones (~20km range), laser-based directed energy weapons, robotics, and autonomous ground vehicles, with these technologies expected to mature over the next 2-3 years and support long-term growth.

Financial outlook

We broadly maintain our estimates and expect revenue/EBITDA/PAT CAGR of 60%/67%/54% over FY26-29E, with an EBITDA margin of ~36% for FY27-29. Subsidiaries' contributions to consolidated numbers are also expected to improve meaningfully over the next two years.

Valuation and view

The stock currently trades at 50.3x/35.9x/28.7x P/E on FY27/28/29E earnings. We **reiterate our Neutral rating on the stock with an unchanged TP of INR1,600, based on 30x Sep'28E earnings.**

Key risks and concerns


Any slowdown in procurement from the defense industry, especially for simulators, can expose the company to the risk of reduced order inflows and hinder its growth. ZEN is also exposed to foreign currency risk due to its export revenue.

Standalone - Quarterly Earnings
(INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Est
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	Var (%)
Net Sales	1,111	1,247	1,162	719	1,030	2,181	2,776	3,928	4,238	9,916	1,091	(6)
YoY Change (%)	(56.3)	(48.4)	(17.9)	(75.5)	(7.3)	75.0	139.0	446.3	(54.5)	134.0	(1.8)	
Total Expenditure	730	829	636	683	747	1,462	1,846	2,305	2,877	6,360	780	(4)
EBITDA	380	418	526	36	282	720	930	1,624	1,360	3,556	311	(9)
YoY Change (%)	(63.1)	(47.4)	43.2	(96.2)	(25.8)	72.2	76.8	4,427.2	(56.6)	161.4	(18.3)	
Margins (%)	34.3	33.5	45.3	5.0	27.4	33.0	33.5	41.3	32.1	35.9	28.5	
Depreciation	31	33	36	37	47	38	39	32	137	156	37	27
Interest	14	4	10	6	5	8	9	12	34	34	8	(36)
Other Income	199	230	143	200	175	177	177	180	772	709	182	(4)
PBT	535	610	624	192	405	851	1,060	1,759	1,961	4,075	448	(9)
Tax	164	149	145	45	113	218	271	441	502	1,044	115	(1)
Rate (%)	30.6	24.4	23.3	23.2	27.9	25.6	25.6	25.1	25.6	25.6	25.6	
Reported PAT	371	462	478	147	292	633	788	1,318	1,459	3,031	333	(12)
Adj PAT	371	462	478	147	292	633	788	1,318	1,459	3,031	333	(12)
YoY Change (%)	(50.0)	(29.2)	23.8	(82.6)	(21.3)	37.1	64.9	793.6	(44.5)	107.8	(10.3)	
Margins (%)	33.4	37.0	41.2	20.5	28.4	29.0	28.4	33.5	34.4	30.6	30.5	


Key Exhibits

Exhibit 1: Total revenue declined 7% YoY on slower-than-expected execution




Source: Company, MOFSL

Exhibit 2: Share of revenue from equipment sales remained a major contributor




Source: Company, MOFSL

Exhibit 3: Order book jumped 88% YoY on improved ordering during 2HFY26




Source: Company, MOFSL

Exhibit 4: Share of equipment in overall order book increased due to ramp-up in inflows during 2HFY26




Source: Company, MOFSL

Exhibit 5: EBITDA declined due to fixed cost absorption




Source: Company, MOFSL

Exhibit 6: PAT declined 21% YoY



Source: Company, MOFSL

Exhibit 7: Gross margin remained strong during the quarter; however, EBITDA margin dipped due to operating leverage from lower revenue absorption of fixed costs, along with higher warranty provisions and increased R&D spending



Source: Company, MOFSL

Exhibit 8: Comparison of key metrics of ZEN on a standalone and consolidated basis

Zen Technologies INR m	1QFY27		
	Standalone	Consolidated	Subsidiaries
Order book	11,388	12,390	1,003
Revenue	1,030	1,416	387
YoY growth (%)	-7.3	-10.5	NM
EBITDA	282	387	105
YoY growth (%)	-25.8	-40.2	NM
Margin (%)	27.4	27.3	27.2
Adj PAT	292	378	86
YoY growth (%)	-21.3	-20.8	NM
Margin (%)	28.4	26.7	22.3

Source: Company, MOFSL

Exhibit 9: Proforma consolidated income statement of ZEN (INR m)

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Total Income from Operations	1,493	546	698	2,188	4,399	9,736	6,877	13,267	17,936	22,526
Change (%)	61.9	-63.4	27.7	213.7	101.0	121.4	-29.4	92.9	35.2	25.6
Total Expenditure	866	473	652	1,462	2,591	6,001	4,404	8,371	11,346	14,253
% of Sales	58.0	86.5	93.5	66.8	58.9	61.6	64.0	63.1	63.3	63.3
EBITDA	627	74	46	726	1,808	3,735	2,472	4,896	6,590	8,273
Margin (%)	42.0	13.5	6.5	33.2	41.1	38.4	36.0	36.9	36.7	36.7
Depreciation	46	50	48	61	97	154	244	279	334	392
EBIT	582	24	-3	666	1,711	3,581	2,229	4,618	6,256	7,881
Int. and Finance Charges	33	11	15	41	23	104	103	135	160	185
Other Income	19	30	54	72	149	584	854	810	1,061	1,193
PBT bef. EO Exp.	567	44	36	697	1,837	4,061	2,980	5,293	7,157	8,889
EO Items	0	0	3	-20	-24	0	9	0	0	0
PBT after EO Exp.	567	44	33	717	1,862	4,061	2,971	5,293	7,157	8,889
Total Tax	-19	16	7	218	566	1,067	787	1,397	1,882	2,336
Tax Rate (%)	-3.4	36.4	21.0	30.3	30.4	26.3	26.5	26.4	26.3	26.3
Share of P/L from JV and MI	-1	-3	6	72	16	191	268	304	363	437
Reported PAT	588	31	20	427	1,279	2,802	1,916	3,592	4,912	6,116
Adjusted PAT	588	31	23	407	1,255	2,802	1,925	3,592	4,912	6,116
Change (%)	341.4	-94.7	-27.2	1,698.8	208.0	123.3	-31.3	86.6	36.8	24.5
Margin (%)	39.4	5.7	3.2	18.6	28.5	28.8	28.0	27.1	27.4	27.2

Source: Company, MOFSL

Exhibit 10: ZEN's subsidiaries and their offerings



Source: Company

Financial outlook

Exhibit 11: We expect revenue to grow going forward, driven by higher order inflows




Exhibit 12: We expect gross margin to remain at comfortable levels of ~60%




Exhibit 13: We expect EBITDA margin to remain at ~36%




Exhibit 14: We expect PAT CAGR of ~54% over FY26-29




Exhibit 15: OCF and FCF to be lumpy over the years




Exhibit 16: We expect RoE/RoCE to be at ~15-19%





Exhibit 17: With an improved product mix, we expect the asset turnover ratio to improve beyond FY26



Source: Company, MOFSL

Financials and valuations

Standalone - Income Statement

(INR m)

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Total Income from Operations	1,470	496	537	1,614	4,303	9,307	4,238	9,916	13,746	17,499
Change (%)	59.4	-66.3	8.4	200.6	166.5	116.3	-54.5	134.0	38.6	27.3
Raw Materials	390	80	83	408	1,373	4,402	1,589	3,966	5,498	6,999
Gross Profit	1,080	416	454	1,206	2,930	4,904	2,649	5,949	8,247	10,499
Employee Cost	167	127	148	228	432	570	562	645	825	1,050
Other Expenses	278	211	289	465	726	1,197	726	1,749	2,425	3,087
Total Expenditure	834	418	520	1,102	2,530	6,169	2,877	6,360	8,748	11,136
% of Sales	56.7	84.3	96.8	68.2	58.8	66.3	67.9	64.1	63.6	63.6
EBITDA	636	78	17	513	1,772	3,137	1,360	3,556	4,998	6,362
Margin (%)	43.3	15.7	3.2	31.8	41.2	33.7	32.1	35.9	36.4	36.4
Depreciation	38	40	37	44	73	101	137	156	192	229
EBIT	599	38	-20	469	1,699	3,036	1,223	3,400	4,805	6,133
Int. and Finance Charges	32	10	14	20	18	94	34	34	34	34
Other Income	19	29	53	91	139	578	772	709	935	1,042
PBT bef. EO Exp.	586	57	19	539	1,820	3,520	1,961	4,075	5,706	7,141
EO Items	-1	0	-2	14	-24	0	0	0	0	0
PBT after EO Exp.	587	57	20	525	1,844	3,520	1,961	4,075	5,706	7,141
Total Tax	-20	16	-2	163	552	890	502	1,044	1,461	1,829
Tax Rate (%)	-3.3	27.8	-7.9	31.0	29.9	25.3	25.6	25.6	25.6	25.6
Reported PAT	606	41	22	362	1,292	2,630	1,459	3,031	4,245	5,312
Adjusted PAT	605	41	20	376	1,268	2,630	1,459	3,031	4,245	5,312
Change (%)	214.4	-93.2	-50.5	1,753.7	237.0	107.3	-44.5	107.8	40.0	25.1
Margin (%)	41.2	8.3	3.8	23.3	29.5	28.3	34.4	30.6	30.9	30.4

Standalone - Balance Sheet

(INR m)

Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Equity Share Capital	77	80	80	80	84	90	90	90	90	90
Total Reserves	1,910	2,052	2,837	3,112	4,447	16,800	18,129	21,161	25,405	30,718
Net Worth	1,988	2,132	2,917	3,192	4,531	16,890	18,220	21,251	25,496	30,808
Minority Interest	0	0	0	0	0	0	0	0	0	0
Total Loans	9	9	123	59	0	522	0	0	0	0
Deferred Tax Liabilities	-203	-206	-201	-134	63	2	29	29	29	29
Capital Employed	1,794	1,935	2,839	3,117	4,595	17,414	18,249	21,280	25,525	30,837
Gross Block	995	1,012	1,016	1,142	1,326	1,689	2,050	2,600	3,150	3,700
Less: Accum. Deprn.	351	391	425	468	541	642	767	923	1,115	1,344
Net Fixed Assets	644	621	591	674	785	1,047	1,283	1,677	2,035	2,355
Goodwill on Consolidation	0	0	0	0	0	0	0	0	0	0
Capital WIP	0	0	25	19	107	70	151	151	151	151
Total Investments	159	241	243	243	263	2,185	2,839	2,839	2,839	2,839
Curr. Assets, Loans & Adv.	1,128	1,169	2,517	3,394	6,029	15,452	15,070	18,041	22,480	28,012
Inventory	104	86	142	411	1,334	510	839	544	754	959
Account Receivables	444	174	196	662	1,691	3,784	1,317	4,032	5,589	7,115
Cash and Bank Balance	185	333	761	1,472	1,422	2,741	2,228	10,519	12,052	14,737
Loans and Advances	299	563	1,404	812	1,564	8,404	10,617	2,933	4,066	5,176
Other Current Asset	96	13	15	36	17	13	68	14	20	25
Curr. Liability & Prov.	138	95	538	1,213	2,589	1,340	1,094	1,428	1,980	2,520
Account Payables	111	78	520	1,190	2,559	1,309	1,058	1,395	1,934	2,462
Other Current Liabilities	16	17	18	23	0	0	0	0	0	0
Provisions	10	1	0	0	31	31	36	33	46	59
Net Current Assets	990	1,074	1,979	2,181	3,440	14,112	13,976	16,613	20,500	25,492
Appl. of Funds	1,793	1,935	2,839	3,117	4,595	17,414	18,249	21,280	25,525	30,837

Financials and valuations

Ratios										
Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Basic (INR)										
EPS	6.7	0.5	0.2	4.2	14.0	29.1	16.2	33.6	47.0	58.8
Cash EPS	7.1	0.9	0.6	4.7	14.9	30.2	17.7	35.3	49.1	61.4
BV/Share	22.0	23.6	32.3	35.4	50.2	187.1	201.8	235.4	282.4	341.2
DPS	0.4	0.1	0.1	0.2	1.0	2.0	1.0	0.0	0.0	0.0
Payout (%)	5.1	19.4	39.2	4.2	6.6	6.9	6.2	0.0	0.0	0.0
Valuation (x)										
P/E	252.0	3,720.6	7,514.5	405.4	120.3	58.0	104.6	50.3	35.9	28.7
Cash P/E	237.3	1,885.6	2,648.3	363.1	113.7	55.9	95.6	47.9	34.4	27.5
P/BV	76.8	71.6	52.3	47.8	33.7	9.0	8.4	7.2	6.0	5.0
EV/Sales	103.7	307.1	282.8	93.6	35.1	16.2	35.5	14.3	10.2	7.9
EV/EBITDA	239.6	1,961.6	8,831.8	294.7	85.3	47.9	110.5	39.9	28.1	21.7
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0
FCF per share	6.9	1.3	-5.2	9.7	-0.5	0.1	20.3	84.3	7.0	18.6
Return Ratios (%)										
RoE	35.6	2.0	0.8	12.3	32.8	24.6	8.3	15.4	18.2	18.9
RoCE	33.4	2.3	1.4	12.3	33.1	24.6	8.3	15.5	18.3	19.0
RoIC	42.2	1.9	-1.4	20.3	56.9	29.8	7.2	24.3	39.2	38.7
Working Capital Ratios										
Fixed Asset Turnover (x)	1.5	0.5	0.5	1.4	3.2	5.5	2.1	3.8	4.4	4.7
Asset Turnover (x)	0.8	0.3	0.2	0.5	0.9	0.5	0.2	0.5	0.5	0.6
Inventory (Days)	26	64	96	93	113	20	72	20	20	20
Debtor (Days)	110	128	133	150	143	148	113	148	148	148
Creditor (Days)	28	57	353	269	217	51	91	51	51	51
Leverage Ratio (x)										
Current Ratio	8.2	12.3	4.7	2.8	2.3	11.5	13.8	12.6	11.4	11.1
Interest Cover Ratio	18.8	3.8	-1.4	23.1	92.3	32.2	35.7	99.1	140.1	178.8
Net Debt/Equity	-0.2	-0.3	-0.3	-0.5	-0.4	-0.3	-0.3	-0.6	-0.6	-0.6

Standalone - Cashflow Statement										(INR m)
Y/E Mar	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
OP/(Loss) before Tax	586	57	19	539	1,844	3,520	1,961	4,075	5,706	7,141
Depreciation	38	40	37	44	73	101	137	156	192	229
Interest & Finance Charges	23	-15	-30	-48	12	59	9	34	34	34
Direct Taxes Paid	-114	-28	-12	-87	-321	-984	-560	-1,044	-1,461	-1,829
(Inc)/Dec in WC	111	74	-452	537	-1,405	-2,005	1,409	5,654	-2,354	-2,306
CF from Operations	643	127	-439	985	204	691	2,956	8,875	2,117	3,269
Others	1	0	1	8	10	-381	-671	-709	-935	-1,042
CF from Operating incl EO	644	127	-438	993	214	310	2,285	8,166	1,182	2,227
(Inc)/Dec in FA	-23	-10	-36	-121	-260	-298	-453	-550	-550	-550
Free Cash Flow	622	117	-474	872	-46	12	1,832	7,616	632	1,677
(Pur)/Sale of Investments	-26	-82	-3	-25	-42	-1,922	-658	0	0	0
Others	-62	-84	-393	119	-518	-8,177	-524	709	935	1,042
CF from Investments	-110	-176	-432	-27	-820	-10,397	-1,635	159	385	492
Issue of Shares	0	0	0	0	0	9,802	0	0	0	0
Inc/(Dec) in Debt	-154	-1	865	-64	-58	507	-518	0	0	0
Interest Paid	-32	-5	-9	-16	-12	-44	-13	-34	-34	-34
Dividend Paid	-23	-32	-8	-8	-17	-90	-180	0	0	0
Others	-5	134	25	-97	26	-7	8	0	0	0
CF from Fin. Activity	-214	97	873	-184	-62	10,169	-703	-34	-34	-34
Inc/Dec of Cash	321	47	3	782	-668	82	-53	8,291	1,533	2,685
Opening Balance	-225	96	144	147	929	261	342	2,228	10,519	12,052
Other Bank Balances	89	189	614	543	1,161	2,398	1,939	0	0	0
Closing Balance	185	333	761	1,472	1,422	2,741	2,228	10,519	12,052	14,737

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlineinreports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://qalaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh

Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.